Prostate Cancer - Results from #20020

Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer - Abstract September 26, 2014

No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide - Abstract September 26, 2014

Bone complications among prostate cancer survivors: Long-term follow-up from the prostate cancer outcomes study - Abstract September 26, 2014

Identifying suicidal symptoms in prostate cancer survivors using brief self-report - Abstract September 26, 2014

Next-generation prostate-specific antigen test: Precursor form of prostate-specific antigen - Abstract September 26, 2014

A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels - Abstract September 26, 2014

Random variation in rectal position during radiotherapy for prostate cancer is two to three times greater than that predicted from prostate motion - Abstract September 26, 2014

PROVENGE® (sipuleucel-T) demonstrates positive immune responses when sequenced with other therapies in advanced prostate cancer September 26, 2014

Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 Case reports and literature review - Abstract September 26, 2014

Incidence and clinicopathological characteristics of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens - Abstract September 25, 2014

Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients - Abstract September 25, 2014

Cardiovascular risk profile of veteran men beginning androgen deprivation therapy - Abstract September 25, 2014

New era of the treatment of CRPC in Japan - Abstract September 25, 2014

Predicting the Gleason sum of a patient with a prostate biopsy core Gleason ≤ 7 and a prostate biopsy core Gleason ≥ 8 - Abstract September 25, 2014

Effect of histological inflammation on total and free serum prostate-specific antigen values in patients without clinically detectable prostate cancer - Abstract September 25, 2014

Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities - Abstract September 25, 2014

Enzalutamide in European and North American men participating in the AFFIRM trial - Abstract September 25, 2014

Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases - Abstract September 25, 2014

Perioperative changes in pro and anticoagulant factors in prostate cancer patients undergoing laparoscopic and robotic radical prostatectomy with different anaesthetic techniques - Abstract September 25, 2014

Survival disparities between Māori and non-Māori men with prostate cancer in New Zealand - Abstract September 25, 2014

Page 1002 of 1455